Contrast agents in dynamic contrast-enhanced magnetic resonance imaging

Yan, Yuling; Sun, Xilin; Shen, Baogen

doi:10.18632/oncotarget.16482

Cited by 44 publications

(32 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent data suggest that primary tumor assessment with dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) may reveal quantitative assessments of the tumor environment that are germane to treatment selection and response evaluation 3 . Currently, gadolinium is the standard of care contrast agent for DCE-MRI 4 . However, a large array of potential MR contrast agents exists, including ultra-small superparamagnetic iron oxides (USPIO).…”

Section: Background and Summarymentioning

confidence: 99%

Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors

et al. 2020

View full text Add to dashboard Cite

Node positive head and neck squamous cell carcinomas (HNSCCs) patients exhibit worse outcomes in terms of regional neck control, risk for distant metastases and overall survival. Smaller non-palpable lymph nodes may be inflammatory or may harbor clinically occult metastases, a characterization that can be challenging to make using routine imaging modalities. Ferumoxytol has been previously investigated as an intra-tumoral contrast agent for magnetic resonance imaging (MRI) for intracranial malignancies and lymph node agent in prostate cancer. Hence, our group was motivated to carry out a prospective feasibility study to assess the feasibility of ferumoxytol dynamic contrast enhanced (DCE)weighted MRI relative to that of gadolinium-based DCE-MRI for nodal and primary tumor imaging in patients with biopsy-proven node-positive HNSCC or melanoma. although this institutional review board (IRB)-approved study was prematurely terminated because of an FDa black box warning, the investigators sought to curate and publish this unique dataset of matched clinical, and anatomical and DCE MRI data for the enrolled five patients to be available for scientists interested in molecular imaging. Record System), a custom-built electronic medical record system by MDACC, that started in 1999 with subsequent significant improvement in 2007 that allowed further new capabilities, such as integrating research data and accessing data from virtually every electronic source within the institution, thus serving a great role in patient care and research. http://www.clinfowiki.org/wiki/index.php/ ClinicStation. ClinicStation (Electronic Medical Usage NotesWe invite all interested researchers to download this dataset of matched clinical-imaging dataset including DCE/ DSC-weighted perfusion MRI acquisitions in immobilization position using an under-investigated contrast agent in the setting of HNSCC imaging. Moreover, this data descriptor serves as a report for the only trial that prospectively investigated the feasibility of USPIO as a contrast agent for DCE-MRI acquisition purposes in the setting of head and neck cancer imaging.

show abstract

Section: Background and Summarymentioning

confidence: 99%

Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Another imaging modality is DCE MRI, which can measure the perfusion in tissue using contrast media agents [8] . Several parameters can be obtained with this technique, namely, K trans , K ep , and V e [8] . K trans is the volume transfer constant, V e is the extravascular extracellular volume fraction, and K ep is the flux rate constant [8] .…”

Section: Introductionmentioning

confidence: 99%

“…Several parameters can be obtained with this technique, namely, K trans , K ep , and V e [8] . K trans is the volume transfer constant, V e is the extravascular extracellular volume fraction, and K ep is the flux rate constant [8] . It is widely acknowledged that DCE parameters, especially K trans , are associated with microvessel density in tissues, [8] , [9] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Two Mathematical Models of Cellularity Calculation

Meyer

Garnov

2018

Translational Oncology

View full text Add to dashboard Cite

OBJECT: Nowadays, there is increasing evidence that functional magnetic resonance imaging (MRI) modalities, namely, diffusion-weighted imaging (DWI) and dynamic-contrast enhanced MRI (DCE MRI), can characterize tumor architecture like cellularity and vascularity. Previously, two formulas based on a logistic tumor growth model were proposed to predict tumor cellularity with DWI and DCE. The purpose of this study was to proof these formulas. METHODS: 16 patients with head and neck squamous cell carcinomas were included into the study. There were 2 women and 14 men with a mean age of 57.0 ± 7.5 years. In every case, tumor cellularity was calculated using the proposed formulas by Atuegwu et al. In every case, also tumor cell count was estimated on histopathological specimens as an average cell count per 2 to 5 high-power fields. RESULTS: There was no significant correlation between the calculated cellularity and histopathologically estimated cell count by using the formula based on apparent diffusion coefficient (ADC) values. A moderate positive correlation (r=0.515, P=.041) could be identified by using the formula including ADC and Ve values. CONCLUSIONS: The formula including ADC and Ve values is more sensitive to predict tumor cellularity than the formula including ADC values only.

show abstract

“…The advantage of DW imaging to help visualize residual breast cancer without the need for contrast medium could be advantageous in women with impaired renal function (5) .Dynamic contrast agent-enhanced (DCE) magnetic resonance (MR) imaging can depict the distribution of a contrast agent within a tumor over time and noninvasively assess the tissue vasculature. A recent prospective multicenter trial with DCE MR imaging reported that tumor volume measurements were superior to either clinical assessment or diameter measurement in the prediction of pathologic complete response pCR after NAC (6) . Another study had previously reported that the initial MR imaging tumor volume and its change after NAC were predictive of recurrence-free survival in breast cancer patients (7) .…”

Section: Introductionmentioning

confidence: 99%

Role of Advanced MRI Techniques in Evaluating the Response of Breast Cancer to Neoadjuvant Chemotherapy

Mohamed¹,

Habeeb²,

Chalabi³

2018

Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Neoadjuvant chemotherapy (NAC) is the favored treatment of choice among locally advanced breast cancer patients because it significantly increases the possibility of breast-conserving surgery. However, for non-responders, an early prediction of response to NAC is essential. Magnetic resonance imaging (MRI) of the breast is an adjunct diagnostic procedure to mammography and ultrasound. Because of its high sensitivity and effectiveness in dense breast tissue, MRI can be a valuable addition to the diagnostic work-up of a patient with breast abnormality or biopsy-proven cancer. Aim of the Work: To highlight the role of advanced MRI techniques in the prediction and follow up of the response of breast cancer to neoadjuvant chemotherapy. Conclusion: Early change in tumor size measured on MR images is a good predictor of final response after Neoadjuvant chemotherapy (NAC). However, even if the cells respond to treatment, it takes some time for the tumor to shrink. Substantial research effort has been spent on investigating whether other information provided by MR imaging may serve as earlier response indicators than change in tumor size. Techniques that seem to be closest to clinical application, due to their feasibility and the promising results, are the pharmacokinetic analysis of DCE-MRI (Dynamic Contrast Enhanced-MRI), DW-MRI (Diffusion Weighted-MRI) and Spectroscopy.

show abstract

Contrast agents in dynamic contrast-enhanced magnetic resonance imaging

Cited by 44 publications

References 83 publications

Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors

Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors

Comparison of Two Mathematical Models of Cellularity Calculation

Role of Advanced MRI Techniques in Evaluating the Response of Breast Cancer to Neoadjuvant Chemotherapy

Contact Info

Product

Resources

About